Investigating methods regarding diagnostic and prognostic biomarkers for malignant mesothelioma

Malignant mesothelioma (MM) is a pleural malignant tumor that results predominantly from exposure to asbestos and has a poor prognosis. After a brief review of the epidemiology, etiology, and clinical status of MM, we detail methods being used to search for diagnostic and prognostic biomarkers for MM, particularly approaches involving the use of blood samples. The soluble mesothelin-related protein (SMRP), mesothelin/ERC and osteopontin are typical biomarkers for MM. In addition to these biomarkers, fibulin-3 has recently been introduced as a biomarker for MM. Furthermore, several molecules have been reported as useful biomarkers. In addition to an introduction outlining newer approaches such as those of proteomics, we hope to summarize the recent status of biomarkers for MM in this review.

[1]  J. Lange,et al.  Non-asbestos Causes of mesothelioma and translocation of asbestos fibres. , 2015, Singapore medical journal.

[2]  M. Bayram,et al.  Fibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[3]  N. Reguart,et al.  Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies. , 2015, Cancer treatment reviews.

[4]  M. Bovenzi,et al.  Increased Levels of C-C Chemokine RANTES in Asbestos Exposed Workers and in Malignant Mesothelioma Patients from an Hyperendemic Area , 2014, PloS one.

[5]  G. Nilsonne,et al.  Diagnostic and Prognostic Value of Soluble Syndecan-1 in Pleural Malignancies , 2014, BioMed research international.

[6]  S. Antoniu,et al.  Immune therapies for malignant mesothelioma , 2014, Expert review of anticancer therapy.

[7]  S. Skates,et al.  Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma , 2014, Thorax.

[8]  Kazuhisa Takahashi,et al.  Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma , 2014, Cancer medicine.

[9]  B. Ghanim,et al.  Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma , 2014, British Journal of Cancer.

[10]  Masami Watanabe,et al.  Adenovirus-mediated REIC/Dkk-3 gene therapy: Development of an autologous cancer vaccination therapy (Review) , 2013, Oncology letters.

[11]  M. Maeda,et al.  Retrospective analysis of large-scale research screening of construction workers for the early diagnosis of mesothelioma. , 2014, Molecular and clinical oncology.

[12]  A. Casalini,et al.  YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis. , 2013, Anticancer research.

[13]  R. Aebersold,et al.  Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring , 2013, Clinical Proteomics.

[14]  T. Nakano,et al.  Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma. , 2013, Molecular and clinical oncology.

[15]  G. Nilsonne,et al.  Hyaluronan and N-ERC/Mesothelin as Key Biomarkers in a Specific Two-Step Model to Predict Pleural Malignant Mesothelioma , 2013, PloS one.

[16]  D. Henderson,et al.  Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA , 2013, Journal of Clinical Pathology.

[17]  Y. Sekido.  Molecular pathogenesis of malignant mesothelioma. , 2013, Carcinogenesis.

[18]  D. Henderson,et al.  Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers , 2013, Journal of Clinical Pathology.

[19]  H. Pass,et al.  Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. , 2012, The New England journal of medicine.

[20]  Stephen A. Williams,et al.  Early Detection of Malignant Pleural Mesothelioma in Asbestos-Exposed Individuals with a Noninvasive Proteomics-Based Surveillance Tool , 2012, PloS one.

[21]  M. Maeda,et al.  The utility of serum N-ERC/mesothelin as a biomarker of ovarian carcinoma. , 2012, Oncology letters.

[22]  J. Kanno,et al.  Dose-dependent mesothelioma induction by intraperitoneal administration of multi-wall carbon nanotubes in p53 heterozygous mice , 2012, Cancer science.

[23]  Y. Takeshima,et al.  National survey of malignant mesothelioma and asbestos exposure in Japan , 2012, Cancer science.

[24]  V. Dolžan,et al.  Soluble Mesothelin-Related Peptides Levels in Patients with Malignant Mesothelioma , 2012, Disease markers.

[25]  H. Matsuzaki,et al.  Asbestos-Induced Cellular and Molecular Alteration of Immunocompetent Cells and Their Relationship with Chronic Inflammation and Carcinogenesis , 2012, Journal of biomedicine & biotechnology.

[26]  R. Stahel,et al.  Proteomic surfaceome analysis of mesothelioma. , 2012, Lung cancer.

[27]  Kenichi Azuma,et al.  Future trends of mesothelioma mortality in Japan based on a risk function. , 2012, Industrial health.

[28]  T. Nakano,et al.  Pathological and molecular biological approaches to early mesothelioma , 2012, International Journal of Clinical Oncology.

[29]  S. Toyokuni,et al.  Asbestos surface provides a niche for oxidative modification , 2011, Cancer science.

[30]  S. Toyokuni,et al.  Diameter and rigidity of multiwalled carbon nanotubes are critical factors in mesothelial injury and carcinogenesis , 2011, Proceedings of the National Academy of Sciences.

[31]  G. Ceresoli,et al.  Advances in the biology of malignant pleural mesothelioma. , 2011, Cancer treatment reviews.

[32]  H. Matsuzaki,et al.  Asbestos Induces Reduction of Tumor Immunity , 2011, Clinical & developmental immunology.

[33]  T. Otsuki,et al.  Decreased CXCR3 expression in CD4+ T cells exposed to asbestos or derived from asbestos-exposed patients. , 2011, American journal of respiratory cell and molecular biology.

[34]  T. Otsuki,et al.  Reduction of CXC chemokine receptor 3 in an in vitro model of continuous exposure to asbestos in a human T-cell line, MT-2. , 2011, American journal of respiratory cell and molecular biology.

[35]  N. Cox,et al.  Germline BAP1 mutations predispose to malignant mesothelioma , 2011, Nature Genetics.

[36]  M. Nagendran,et al.  Should all patients who have mesothelioma diagnosed by video-assisted thoracoscopic surgery have their intervention sites irradiated? , 2011, Interactive cardiovascular and thoracic surgery.

[37]  C. Sander,et al.  The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma , 2011, Nature Genetics.

[38]  D. Henderson,et al.  The Molecular Pathogenesis of Asbestos-Related Disorders , 2011 .

[39]  Y. Sekido.  Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation , 2011, Pathology international.

[40]  K. Kiura,et al.  Medical Treatment of Mesothelioma: Anything New? , 2011, Current oncology reports.

[41]  N. Maskell,et al.  Biopsy techniques for the diagnosis of mesothelioma. , 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[42]  A. Chella,et al.  Comparison between Plasma and Serum Osteopontin Levels: Usefulness in Diagnosis of Epithelial Malignant Pleural Mesothelioma , 2010, The International journal of biological markers.

[43]  D. Sugarbaker,et al.  Surgery for malignant pleural mesothelioma , 2010, Expert review of respiratory medicine.

[44]  S. Ozaki,et al.  Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma. , 2010, Experimental and therapeutic medicine.

[45]  T. Otsuki,et al.  Decrease in Phosphorylation of ERK following Decreased Expression of NK Cell-Activating Receptors in Human NK Cell Line Exposed to Asbestos , 2009, International journal of immunopathology and pharmacology.

[46]  H. Kindler,et al.  Malignant pleural mesothelioma: an update on biomarkers and treatment. , 2009, Chest.

[47]  T. Nakano,et al.  Impairment in Cytotoxicity and Expression of NK Cell- Activating Receptors on Human NK Cells following Exposure to Asbestos Fibers , 2009, International journal of immunopathology and pharmacology.

[48]  Stacey Su.  Mesothelioma: path to multimodality treatment. , 2009, Seminars in thoracic and cardiovascular surgery.

[49]  Ignacio Wistuba,et al.  Malignant Pleural Mesothelioma , 2017 .

[50]  I. Uchiyama,et al.  Mesothelioma Risk and Environmental Exposure to Asbestos: Past and Future Trends in Japan , 2009, International journal of occupational and environmental health.

[51]  J. Dunning,et al.  Does video-assisted thoracoscopic decortication in advanced malignant mesothelioma improve prognosis? , 2009, Interactive Cardiovascular and Thoracic Surgery.

[52]  Eun‐Kee Park,et al.  Osteopontin Levels in an Asbestos-Exposed Population , 2009, Clinical Cancer Research.

[53]  A. Marchevsky.  Application of immunohistochemistry to the diagnosis of malignant mesothelioma. , 2009, Archives of pathology & laboratory medicine.

[54]  M. Sakaguchi,et al.  Down-regulation of inhibition of differentiation-1 via activation of activating transcription factor 3 and Smad regulates REIC/Dickkopf-3-induced apoptosis. , 2008, Cancer research.

[55]  A. Gibbs,et al.  Malignant Diseases of the Pleura, Peritoneum, and Other Serosal Surfaces , 2008 .

[56]  Haydn Adams,et al.  Radiological Features of the Asbestos-Associated Diseases , 2008 .

[57]  D. Weill.  Diagnostic Features and Clinical Evaluation of the Asbestos-Associated Diseases , 2008 .

[58]  C. Palumbo,et al.  Molecular targets and targeted therapies for malignant mesothelioma. , 2008, Current medicinal chemistry.

[59]  T. Nakano.  Current therapies for malignant pleural mesothelioma , 2008, Environmental health and preventive medicine.

[60]  K. Inai.  Pathology of mesothelioma , 2008, Environmental health and preventive medicine.

[61]  J. Kanno,et al.  Induction of mesothelioma in p53+/- mouse by intraperitoneal application of multi-wall carbon nanotube. , 2008, The Journal of toxicological sciences.

[62]  H. Pass,et al.  Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. , 2008, The Annals of thoracic surgery.

[63]  T. Brüning,et al.  Soluble mesothelin-related peptides (SMRP) - high stability of a potential tumor marker for mesothelioma. , 2007, Cancer biomarkers : section A of Disease markers.

[64]  M. Copin,et al.  Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. , 2006, American journal of respiratory and critical care medicine.

[65]  塩見 和.  Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients , 2006 .

[66]  Ken Takahashi,et al.  Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. , 2006, American journal of industrial medicine.

[67]  K. Forster,et al.  Radiotherapy for mesothelioma. , 2005, Hematology/oncology clinics of North America.

[68]  A. Musk,et al.  Soluble mesothelin-related protein--a blood test for mesothelioma. , 2005, Lung cancer.

[69]  Zhandong Liu,et al.  Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. , 2005, The New England journal of medicine.

[70]  Neil White,et al.  Asbestos and mesothelioma in South Africa. , 2004, Lung cancer.

[71]  S. Emri,et al.  Malignant pleural mesothelioma in Turkey, 2000-2002. , 2004, Lung cancer.

[72]  Fergus V Gleeson,et al.  Radiology in pleural disease: State of the art , 2004, Respirology.

[73]  T. Sporn,et al.  Cytopathology of Asbestos-Associated Diseases , 2004 .

[74]  C. Higgins,et al.  Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. , 2004, Radiographics : a review publication of the Radiological Society of North America, Inc.

[75]  E. van Marck.  Pathology of malignant mesothelioma. , 2004, Lung cancer.

[76]  V. Au,et al.  Radiological manifestations of malignant pleural mesothelioma. , 2003, Australasian radiology.

[77]  J. Aisner,et al.  Pemetrexed for diffuse malignant pleural mesothelioma. , 2002, Seminars in oncology.

[78]  Edward F Patz,et al.  The role of imaging in malignant pleural mesothelioma. , 2002, Seminars in oncology.

[79]  B. Robinson,et al.  Pathogenesis of Mesothelioma , 2002 .

[80]  Nadgouda Vg,et al.  Malignant pleural mesothelioma. , 2001 .

[81]  U. Hengge.  Gene therapy in mesothelioma , 1998 .

[82]  R. Attanoos,et al.  Pathology of malignant mesothelioma , 1997, Histopathology.

[83]  N. Vogelzang,et al.  Chemotherapy in malignant pleural mesothelioma. A review. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  M. Klockars,et al.  Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma. , 1988, Chest.

[85]  G. De Martini,et al.  [Pathogenesis of mesotheliomas: chronic fibroplastic pleurisy as possible premesothelioma changes]. , 1981, Archivio Monaldi per la tisiologia e le malattie dell'apparato respiratorio.

[86]  M. C. Godwin,et al.  Asbestos and mesothelioma. , 1968, JAMA.

[87]  J. Wagner,et al.  The detection of hyaluronic acid in pleural fluids of cases with diffuse pleural mesotheliomas. , 1963, British journal of experimental pathology.